PURPOSE: We hypothesized that assessment of myocardial sympathetic activity with no-carrier-added (nca) (123)I-meta-iodobenzylguanidine (MIBG) compared to carrier-added (ca) (123)I-MIBG would lead to an improvement of clinical performance without major differences in radiation dosimetry. METHODS: In nine healthy volunteers, 15 min and 4 h planar thoracic scintigrams and conjugate whole-body scans were performed up to 48 h following intravenous injection of 185 MBq (123)I-MIBG. The subjects were given both nca and ca (123)I-MIBG. Early heart/mediastinal ratios (H/M), late H/M ratios and myocardial washout were calculated. The fraction of administered activity in ten source organs was quantified from the attenuation-corrected geometric mean counts in conjugate views. Radiation-absorbed doses were estimated with OLINDA/EXM software. RESULTS: Both early and late H/M were higher for nca (123)I-MIBG (ca (123)I-MIBG early H/M 2.46 +/- 0.15 vs nca (123)I-MIBG 2.84 +/- 0.15, p = 0.001 and ca (123)I-MIBG late H/M 2.69 +/- 0.14 vs nca (123)I-MIBG 3.34 +/- 0.18, p = 0.002). Myocardial washout showed a longer retention time for nca (123)I-MIBG (p < 0.001). The effective dose equivalent (adult male model) for nca (123)I-MIBG was similar to that for ca (123)I-MIBG (0.025 +/- 0.002 mSv/MBq vs 0.026 +/- 0.002 mSv/MBq, p = 0.055, respectively). CONCLUSION: No-carrier-added (123)I-MIBG yields a higher relative myocardial uptake and is associated with a higher myocardial retention. This difference between nca (123)I-MIBG and ca (123)I-MIBG in myocardial uptake did not result in major differences in estimated absorbed doses. Therefore, nca (123)I-MIBG is to be preferred over ca (123)I-MIBG for the assessment of cardiac sympathetic activity.
PURPOSE: We hypothesized that assessment of myocardial sympathetic activity with no-carrier-added (nca) (123)I-meta-iodobenzylguanidine (MIBG) compared to carrier-added (ca) (123)I-MIBG would lead to an improvement of clinical performance without major differences in radiation dosimetry. METHODS: In nine healthy volunteers, 15 min and 4 h planar thoracic scintigrams and conjugate whole-body scans were performed up to 48 h following intravenous injection of 185 MBq (123)I-MIBG. The subjects were given both nca and ca (123)I-MIBG. Early heart/mediastinal ratios (H/M), late H/M ratios and myocardial washout were calculated. The fraction of administered activity in ten source organs was quantified from the attenuation-corrected geometric mean counts in conjugate views. Radiation-absorbed doses were estimated with OLINDA/EXM software. RESULTS: Both early and late H/M were higher for nca (123)I-MIBG (ca (123)I-MIBG early H/M 2.46 +/- 0.15 vs nca (123)I-MIBG 2.84 +/- 0.15, p = 0.001 and ca (123)I-MIBG late H/M 2.69 +/- 0.14 vs nca (123)I-MIBG 3.34 +/- 0.18, p = 0.002). Myocardial washout showed a longer retention time for nca (123)I-MIBG (p < 0.001). The effective dose equivalent (adult male model) for nca (123)I-MIBG was similar to that for ca (123)I-MIBG (0.025 +/- 0.002 mSv/MBq vs 0.026 +/- 0.002 mSv/MBq, p = 0.055, respectively). CONCLUSION: No-carrier-added (123)I-MIBG yields a higher relative myocardial uptake and is associated with a higher myocardial retention. This difference between nca (123)I-MIBG and ca (123)I-MIBG in myocardial uptake did not result in major differences in estimated absorbed doses. Therefore, nca (123)I-MIBG is to be preferred over ca (123)I-MIBG for the assessment of cardiac sympathetic activity.
Authors: Markku S Nieminen; Michael Böhm; Martin R Cowie; Helmut Drexler; Gerasimos S Filippatos; Guillaume Jondeau; Yonathan Hasin; José Lopez-Sendon; Alexandre Mebazaa; Marco Metra; Andrew Rhodes; Karl Swedberg; Silvia G Priori; Maria Angeles Alonso Garcia; Jean-Jacques Blanc; Andrzej Budaj; Martin R Cowie; Veronica Dean; Jaap Deckers; Enrique Fernandez Burgos; John Lekakis; Bertil Lindahl; Gianfranco Mazzotta; João Morais; Ali Oto; Otto A Smiseth; Maria Angeles Alonso Garcia; Kenneth Dickstein; Anibal Albuquerque; Pedro Conthe; Maria Crespo-Leiro; Roberto Ferrari; Ferenc Follath; Antonello Gavazzi; Uwe Janssens; Michel Komajda; João Morais; Rui Moreno; Mervyn Singer; Satish Singh; Michal Tendera; Kristian Thygesen Journal: Eur Heart J Date: 2005-01-28 Impact factor: 29.983
Authors: Robert O Bonow; Susan Bennett; Donald E Casey; Theodore G Ganiats; Mark A Hlatky; Marvin A Konstam; Costas T Lambrew; Sharon-Lise T Normand; Ileana L Piña; Martha J Radford; Andrew L Smith; Lynne Warner Stevenson; Robert O Bonow; Susan J Bennett; Gregory Burke; Kim A Eagle; Harlan M Krumholz; Costas T Lambrew; Jane Linderbaum; Frederick A Masoudi; Sharon-Lise T Normand; James L Ritchie; John S Rumsfeld; John A Spertus Journal: J Am Coll Cardiol Date: 2005-09-20 Impact factor: 24.094
Authors: M W Dae; J W O'Connell; E H Botvinick; T Ahearn; E Yee; J P Huberty; H Mori; M C Chin; R S Hattner; J M Herre Journal: Circulation Date: 1989-03 Impact factor: 29.690
Authors: J Farahati; D Bier; M Scheubeck; M Lassmann; L F Schelper; I Grelle; H Hanscheid; J Biko; K H Graefe; C Reiners Journal: J Nucl Med Date: 1997-03 Impact factor: 10.057
Authors: Hein J Verberne; Derk O Verschure; G Aernout Somsen; Berthe L F van Eck-Smit; Arnold F Jacobson Journal: Eur J Nucl Med Mol Imaging Date: 2011-04-02 Impact factor: 9.236